Tue.Oct 13, 2020

J&J halts studies of coronavirus vaccine due to participant's illness

Bio Pharma Dive

The company did not disclose details, nor could it confirm whether the participant had received its shot. But J&J is now the second vaccine developer, along with AstraZeneca, to suspend testing for a safety review

Relief Therapeutics and NeuroRx Release Promising Data for Potential COVID-19 Treatment


Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

There is value to patients when independent sites offer clinical trials

Bio Pharma Dive

We observe that the COVID-19 crisis shines a light on the benefits to patients and industry stakeholders of bringing clinical trials closer to patients' homes

CDC Finalizes COVID-19 Vaccine Distribution Plan as Vaccine Authorization Nears


With multiple COVID-19 vaccines in development, the CDC is confident that any vaccines the FDA authorizes or approves will be safe because they are based on the FDA’s usual stringent protocols. The greater question, after a vaccine is approved, is how it will be distributed

FDA puts Voyager study on hold in latest gene therapy speed bump

Bio Pharma Dive

The biotech won't be able to start human testing of an experimental Huntington's disease treatment until regulators see more manufacturing data

The Great Barrier Reef has lost half its corals


Credit: Andreas Dietzel. A new study of the Great Barrier Reef shows populations of its small, medium and large corals have all declined in the past three decades.


More Trending

To make mini-organs grow faster, give them a squeeze


Study finds that compressing cells, and crowding their contents, can coax them to grow and divide Credit: Yiwei Li The closer people are physically to one another, the higher the chance for exchange, of things like ideas, information, and even infection.

Dyno Therapeutics Strikes AAV Deal with Roche Worth up to $1.8 Billion


Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually t

Truvada for PrEP: availability, cost and side effects


It is estimated that around 103,800 of people live with HIV in the UK (PHE, 2019). Estimated 17% of people with HIV are not aware of the infection (NICE, 2016), increasing the risk of passing HIV when having sex without protection.

Aimmune Becomes Point Pharmaceutical Business for Nestlé


In August, Nestlé gobbled up Aimmune in a $2.6 billion deal, and now the food allergy-focused company will serve as the point pharmaceutical business for Nestlé Health Science

Sea star’s ability to clone itself may empower this mystery globetrotter


Credit: Michael Boyle For decades, biologists have captured tiny sea star larvae in their nets that did not match the adults of any known species. A Smithsonian team recently discovered what these larvae grow up to be and how a special superpower may help them move around the world.


Taking the Guesswork Out of Workload Planning for Your Clinical Trials

Forte Research Systems®

Learn how tracking staff effort helps sites understand and make better use of their time. Efficient Clinical Trials Metrics Clinical Trial Metrics Forte Insights

NIH-funded study links adolescent brain differences to increased waist circumference


Finding from ABCD Study elucidates neural mechanisms that may underlie early weight gain Credit: Image modified from Rapuano, Laurent et al.

Wasp Venom Shows Potential Against Antibiotic-Resistant Bacteria


Scientists at the University of Pennsylvania hope to use powerful antimicrobial molecules found in the venom of the Vespula lewisii (Korean Yellow-jacket wasp) against the antibiotic-resistant bacteria that cause sepsis and tuberculosis

Controlling the speed of enzyme motors brings biomedical applications of nanorobots closer


New CEO Mortazavi takes UK biotech e-therapeutics into gene silencing

Pharma Phorum

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas.

Plant sciences student receives national honor


The GCSAA Mendenhall Award Recognizes Academic Excellence Credit: Image courtesy UTIA. KNOXVILLE, Tenn.


Pfizer Gets FDA OK to Test Adolescents in COVID-19 Vaccine Trial


To date, all the major clinical trials of vaccines against COVID-19 have been in adults

Scientists shed new light on viruses’ role in coral bleaching


Credit: (photo by Andrew Thurber, OSU). CORVALLIS, Ore. – Scientists at Oregon State University have shown that viral infection is involved in coral bleaching – the breakdown of the symbiotic relationship between corals and the algae they rely on for energy.

Canaan Closes $800 Million VC Fund for Life Sciences and Technology


Venture capital firm Canaan Partners closed on a new fund, it’s twelfth, raising $800 million to invest

DNA-peptide interactions create complex behaviours which may have helped shape biology


Researchers find that simple DNA-peptide interactions create a surprising diversity of compartmentalised higher-ordered phase behaviours, suggesting that these polymers’ primordial interactions helped create modern complex biological structures.

Takeda Joins Forces with Accenture, AWS to Transform to Cloud-Based Company


Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools

An innovative method to tune lasers toward infrared wavelengths


Roche to launch high-volume SARS-CoV-2 antigen test

BioPharma Reporter

Roche plans to launch its high-volume Elecsys SARS-CoV-2 Antigen test at the end of 2020 in markets accepting the CE mark; while the company will file for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). Bio Developments

Finding its way to the top: How a cell surface receptor reaches its destination


Credit: Kim Ratliff, Production Coordinator, Augusta University Dr. Guangyu Wu is dissecting the molecular homing that enables a nascent protein to ultimately find its way to the surface of a cell as a mature receptor type that helps us taste, smell and even regulate our mood and immunity.

COVID-19: Challenges, Innovation, and What’s Ahead in 2021

Pharma Marketing Network

Below is a Q&A with Mark Bard, Co-Founder of The DHC Group, who offers his insights on the challenges COVID-19 has brought to pharma, as well as what innovation is taking place due to this full shift to digital and what lies ahead in the future.

Sales 52

Research demonstrates a molecular dance that keeps your heart beating


Credit: WSU It might look like a little game at the molecular scale. Filament-like proteins in heart muscle cells have to be exactly the same length so that they can coordinate perfectly to make the heart beat.

 ERS Genomics Announces Agreement with FASMAC to Commercialize CRISPR/Cas9 Research Reagents in Japan

BioTech 365

Oncotarget: Genomic markers of midostaurin drug sensitivity in leukemia patients


Oncotarget Volume 11, Issue 29 reported that acute myeloid leukemia is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for Credit: Correspondence to – Mara W.

Dr. Joe Anderson Joins Sofinnova Partners

BioTech 365

Genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks


Codiak Announces Pricing of Initial Public Offering

BioTech 365


Scientists author papers in Nature Astronomy chronicling legacy of Spitzer space telescope


Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

BioTech 365

LEXINGTON, Mass.–(BUSINESS –(BUSINESS WIRE)–Dicerna Pharmaceuticals, Inc. Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,